^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HR negative

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Entrez ID:
Phase 3
UNICANCER
Completed
Last update posted :
02/21/2024
Initiation :
09/01/2007
Primary completion :
06/01/2017
Completion :
09/03/2020
HER-2 • ER • PGR
|
HER-2 negative • HR negative • PGR negative
|
docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin • Ixempra (ixabepilone)
Phase 3
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
02/20/2024
Initiation :
01/06/2021
Primary completion :
01/01/2028
Completion :
05/01/2035
ER • PGR
|
HER-2 positive • ER positive • HR positive • HR negative • ER negative
|
cisplatin • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)
Phase 2
Consorzio Oncotech
Active, not recruiting
Last update posted :
02/01/2024
Initiation :
07/03/2020
Primary completion :
07/03/2024
Completion :
07/03/2024
HER-2 • PD-L1
|
PD-L1 expression • HER-2 negative • HR negative
|
Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel
Phase 2
NRG Oncology
Suspended
Last update posted :
01/30/2024
Initiation :
04/13/2017
Primary completion :
11/30/2024
Completion :
11/30/2024
PD-L1 • PGR
|
HER-2 positive • HR positive • HER-2 negative • HR negative
Phase 2/3
Immutep S.A.S.
Recruiting
Last update posted :
01/19/2024
Initiation :
05/22/2023
Primary completion :
10/31/2026
Completion :
07/31/2027
HER-2 • PD-L1 • ER • PGR
|
ER positive • HR positive • HR negative • PGR positive
|
paclitaxel • ImmuFact (eftilagimod alpha)
Phase N/A
Laura Kennedy
Suspended
Last update posted :
12/12/2023
Initiation :
08/09/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
HER-2 • ER • PGR
|
HER-2 negative • HR negative
Phase 3
University College, London
Recruiting
Last update posted :
11/30/2023
Initiation :
10/01/2015
Primary completion :
10/01/2026
Completion :
10/01/2026
HER-2 • ER
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative
Phase 2
Virginia Commonwealth University
Active, not recruiting
Last update posted :
11/09/2023
Initiation :
01/24/2017
Primary completion :
08/04/2022
Completion :
02/28/2025
HER-2 • PD-L1 • ER • PGR • CD20 • CD8 • CD4 • FOXP3
|
PD-L1 expression • HR positive • HER-2 negative • HR negative
|
Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • azacitidine • albumin-bound paclitaxel • cyclophosphamide • decitabine
Phase 2
Dana-Farber Cancer Institute
Completed
Last update posted :
11/01/2023
Initiation :
05/01/2013
Primary completion :
05/01/2016
Completion :
05/01/2016
HER-2
|
HR positive • HER-2 negative • HR negative
|
Halaven (eribulin mesylate)
Phase 3
Istituto Oncologico Veneto IRCCS
Active, not recruiting
Last update posted :
10/31/2023
Initiation :
06/17/2016
Primary completion :
06/01/2024
Completion :
10/01/2025
HER-2
|
PD-L1 expression • HER-2 amplification • HER-2 negative • HR negative
|
Bavencio (avelumab)
Phase 2
Medical University of Vienna
Recruiting
Last update posted :
10/19/2023
Initiation :
07/01/2023
Primary completion :
05/23/2026
Completion :
05/23/2026
PD-L1
|
HR negative
|
datopotamab deruxtecan (DS-1062a)
Phase 2
Indiana University
Completed
Last update posted :
10/16/2023
Initiation :
07/01/2007
Primary completion :
12/01/2011
Completion :
12/01/2011
ER • PGR
|
HR negative • ER negative • PGR negative
|
cyclophosphamide
Phase 1/2
ImmuneSensor Therapeutics Inc.
Completed
Last update posted :
10/11/2023
Initiation :
09/23/2019
Primary completion :
09/15/2023
Completion :
09/15/2023
PD-L1
|
HR negative
|
IMSA101
Phase 1
Minerva Biotechnologies Corporation
Recruiting
Last update posted :
06/16/2023
Initiation :
01/15/2020
Primary completion :
01/01/2025
Completion :
01/15/2035
HER-2 • PGR • MUC1
|
HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative
|
huMNC2-CAR22 • huMNC2-CAR44 CAR T cells
Phase N/A
Fondazione Policlinico Universitario Agostino G...
Recruiting
Last update posted :
06/07/2023
Initiation :
03/01/2023
Primary completion :
01/01/2024
Completion :
02/01/2024
HER-2
|
HER-2 negative • HR negative
Phase 2
Fudan University
Not yet recruiting
Last update posted :
05/16/2023
Initiation :
07/01/2023
Primary completion :
07/01/2026
Completion :
07/01/2028
HER-2
|
HER-2 positive • HER-2 amplification • HR negative • PGR expression
|
tamoxifen • capecitabine • Irene (pyrotinib) • exemestane
Phase 2
NSABP Foundation Inc
Recruiting
Last update posted :
03/06/2023
Initiation :
05/14/2018
Primary completion :
10/30/2023
Completion :
10/30/2023
HER-2 • PGR
|
HR positive • HER-2 negative • HR negative
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide
Phase 1/2
NSABP Foundation Inc
Completed
Last update posted :
01/26/2023
Initiation :
08/01/2014
Primary completion :
12/01/2020
Completion :
08/01/2021
ER • PGR
|
HR positive • HR negative • EGFR positive
|
Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)
Phase 1b/2
Institut Paoli-Calmettes
Not yet recruiting
Last update posted :
08/29/2022
Initiation :
03/01/2023
Primary completion :
09/01/2027
Completion :
12/01/2027
HER-2 • CDK4 • BRCA
|
HER-2 overexpression • HR negative
|
capecitabine • Zejula (niraparib)
Phase 2
Prof. W. Janni
Active, not recruiting
Last update posted :
07/28/2022
Initiation :
01/01/2014
Primary completion :
12/01/2024
Completion :
12/01/2024
ER • PGR
|
ER positive • HR positive • HR negative • PGR positive
|
Kisqali (ribociclib) • Halaven (eribulin mesylate)
Phase 1
Wake Forest University Health Sciences
Withdrawn
Last update posted :
04/26/2022
Initiation :
04/01/2021
Primary completion :
01/01/2026
Completion :
01/01/2026
HER-2
|
HER-2 overexpression • HER-2 negative • HR negative
|
carboplatin • paclitaxel • doxorubicin hydrochloride • Zejula (niraparib) • cyclophosphamide • Neulasta (pegfilgrastim)
Phase 2
NSABP Foundation Inc
Completed
Last update posted :
10/25/2021
Initiation :
10/01/2010
Primary completion :
09/01/2015
Completion :
11/25/2016
HER-2 • PGR
|
HER-2 positive • HR positive • HR negative
|
Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • doxorubicin hydrochloride • cyclophosphamide
Phase 2
NSABP Foundation Inc
Completed
Last update posted :
10/06/2021
Initiation :
09/01/2012
Primary completion :
03/01/2014
Completion :
10/01/2015
PGR
|
HR positive • HR negative
|
paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Halaven (eribulin mesylate)
Phase 2
Medical University of Gdansk
Not yet recruiting
Last update posted :
10/05/2021
Initiation :
01/01/2022
Primary completion :
01/01/2025
Completion :
12/06/2026
HER-2
|
HER-2 negative • HR negative • PGR expression
|
Ibrance (palbociclib) • carboplatin • paclitaxel
Phase 2
Chinese Academy of Medical Sciences
Recruiting
Last update posted :
06/19/2020
Initiation :
02/01/2020
Primary completion :
01/01/2026
Completion :
12/01/2027
HER-2
|
HER-2 amplification • HER-2 negative • HR negative
|
cyclophosphamide • epirubicin • Pinorubin (pirarubicin)
Phase 3
Fudan University
Completed
Last update posted :
05/19/2020
Initiation :
01/01/2011
Primary completion :
04/20/2016
Completion :
04/20/2016
HER-2 • PGR • BRCA1 • HRD
|
BRCA1 mutation • HER-2 negative • HR negative
|
cisplatin • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • cyclophosphamide • epirubicin
Phase 2
Gynecologic Oncology Group
Completed
Last update posted :
11/19/2019
Initiation :
03/10/2008
Primary completion :
12/11/2013
ER • PGR • BRCA1 • BRCA2 • TGFB1
|
BRCA2 mutation • BRCA1 mutation • HR negative • ER negative • PGR negative
Phase N/A
Agendia
Completed
Last update posted :
06/27/2018
Initiation :
11/01/2015
Primary completion :
04/30/2017
Completion :
08/01/2017
HER-2
|
HER-2 positive • HR positive • HER-2 amplification • HER-2 negative • HR negative • ER positive + PGR positive
Phase 3
Danish Breast Cancer Cooperative Group
Completed
Last update posted :
04/05/2018
Initiation :
06/01/2008
Primary completion :
01/01/2013
Completion :
01/01/2013
HER-2 • PGR • TOP2A
|
HER-2 positive • HR positive • HR negative • PGR negative
|
docetaxel • cyclophosphamide • epirubicin
Phase 1/2
Providence Health & Services
Recruiting
Last update posted :
08/10/2017
Initiation :
02/01/2012
Primary completion :
02/01/2015
Completion :
01/01/2016
CD4
|
HR positive • HR negative
Phase 2
Peking Union Medical College Hospital
Unknown status
Last update posted :
07/20/2016
Initiation :
01/01/2014
Primary completion :
01/01/2020
HER-2 • ER • PGR
|
HER-2 positive • HR negative • PGR negative
|
capecitabine
Phase 1
NSABP Foundation Inc
Completed
Last update posted :
07/08/2014
Initiation :
05/01/2011
Primary completion :
08/01/2012
Completion :
03/01/2014
HER-2
|
HER-2 positive • HR positive • HR negative
|
Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib)